These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1581233)

  • 1. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma.
    Facon T; Caron C; Courtin P; Wurtz A; Deghaye M; Bauters F; Mazurier C; Goudemand J
    Br J Haematol; 1992 Apr; 80(4):488-94. PubMed ID: 1581233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
    Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
    J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment.
    Goudemand J; Samor B; Caron C; Jude B; Gosset D; Mazurier C
    Br J Haematol; 1988 Feb; 68(2):227-33. PubMed ID: 3126793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.
    Richard C; Cuadrado MA; Prieto M; Batlle J; López Fernández MF; Rodriguez Salazar ML; Bello C; Recio M; Santoro T; Gomez Casares MT
    Am J Hematol; 1990 Oct; 35(2):114-7. PubMed ID: 2205095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
    Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
    Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired von Willebrand's disease: a concise review.
    Rinder MR; Richard RE; Rinder HM
    Am J Hematol; 1997 Feb; 54(2):139-45. PubMed ID: 9034288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: unexpected bleeding in the operating room: the role of acquired von Willebrand disease.
    Lison S; Dietrich W; Spannagl M
    Anesth Analg; 2012 Jan; 114(1):73-81. PubMed ID: 22025497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.
    Chilvers GS; Porter G
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25096657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand's disease.
    Hennessy BJ; White B; Byrne M; Smith OP
    Ir J Med Sci; 1998; 167(2):81-5. PubMed ID: 9638020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y; Rick ME
    Proc Natl Acad Sci U S A; 1985 Sep; 82(17):5968-72. PubMed ID: 2994057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.